Education
About Us
Working with TipRanks
Follow Us
CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
RESEARCH TOOLSreports
CAMP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.50 - $12.30
Previous Close$4.45
Volume38.22K
Average Volume (3M)25.35K
Market Cap
$89.11M
Enterprise ValueN/A
Total Cash (Recent Filing)$256.50M
Total Debt (Recent Filing)$275.90M
Price to Earnings (P/E)―
Beta3.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding20,161,074
10 Day Avg. Volume29,532
30 Day Avg. Volume25,353
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.00Price Target Upside307.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
CAMP4 Therapeutics Corporation News
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentA safety review committee has approved dose escalation to the third MAD cohort, in which dosing has been initiated.
Corporate DevelopmentCAMP4 completed a successful IPO issuing 6.82 million CAMP shares at $11.00, raising gross proceeds of $75 million.
Market PotentialCMP-CPS-001 has a larger total addressable market and meets a high unmet need in urea cycle disorders, which presents an upside risk and reward opportunity.
Bears Say
Financial PerformanceG&A expenses of $3.8 million were above the expected $2.9 million.
Regulatory RiskRegRNA therapies may fail in the clinic or to gain approval.
Stock PerformanceShares have fallen 46% in comparison to a 4% drop in the XBI index.
---
Ownership Overview
79.64% Insiders
2.02% Mutual Funds
― Other Institutional Investors
16.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CAMP FAQ
What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?
CAMP4 Therapeutics Corporation lowest stock price was $3.50 and its highest was $12.30 in the past 12 months.
What is CAMP4 Therapeutics Corporation’s market cap?
CAMP4 Therapeutics Corporation’s market cap is $89.11M.
When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CAMP4 Therapeutics Corporation’s earnings last quarter?
CAMP4 Therapeutics Corporation released its earnings results on Nov 21, 2024. The company reported -$24.19 earnings per share for the quarter, missing the consensus estimate of -$1.073 by -$23.117.
Is CAMP4 Therapeutics Corporation overvalued?
According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued.
Does CAMP4 Therapeutics Corporation pay dividends?
CAMP4 Therapeutics Corporation does not currently pay dividends.
What is CAMP4 Therapeutics Corporation’s EPS estimate?
CAMP4 Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CAMP4 Therapeutics Corporation have?
CAMP4 Therapeutics Corporation has 20,161,074 shares outstanding.
What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?
CAMP4 Therapeutics Corporation reported an EPS of -$24.19 in its last earnings report, missing expectations of -$1.073. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?
Currently, no hedge funds are holding shares in CAMP
---
CAMP4 Therapeutics Corporation Stock Smart Score
Company Description
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
---
CAMP Stock 12 Month Forecast
Average Price Target
$18.00
▲(307.24% Upside)
Technical Analysis
Arcturus Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering CAMP
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-25.60%
reiterated a buy rating yesterday
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.60% per trade.
---